TRAIL is a cytokine with a unique ability to induce apoptosis selectively in many transformed cell lines. The instability of TRAIL and the resistance of some cancer cells to TRAIL present the main obstacles for clinical experimentation. We generated an adenovirus expressing full-length TRAIL and tested its efficacy in several cancer cell lines. Ad-TRAIL-infected cancer cells localized full-length TRAIL protein to the cytoplasm and released same-sized TRAIL in the media. Ad-TRAIL was found to induce apoptotic cell death in several cancer cell lines resistant to soluble TRAIL (A549, SKOV3, HT-29 and LNCap) and in TRAIL-sensitive cell lines. Ad-TRAIL, but not soluble TRAIL, induced apoptotic cell death in TRAIL-resistant cell lines, manifested by an increased sub-G1 proportion, caspase-3 activation and PARP cleavage. Ad-TRAIL also induced a media-transferable bystander effect, but only in soluble TRAILsensitive cell lines. In conclusion, two novel characteristics of ad-TRAIL were found during this study. First, that ad-TRAIL can induce apoptotic cell death in several cancer cell lines resistant to sTRAIL. Second, that ad-TRAIL induces a media-transferable bystander effect, which is expected to increase its therapeutic value by allowing TRAIL to overcome the locally acting nature and low transduction rate commonly encountered in clinical situation.
T umor necrosis factor related apoptosis inducing ligand (TRAIL) is a cytokine of the TNF family and has the unique ability to induce apoptosis in many transformed cell lines, but not in normal tissue.
1,2 TRAIL is a type II transmembrane protein that is degraded to soluble TRAIL (sTRAIL), which binds to DR4 and DR5 and induces apoptosis in transformed cells. 2 Normal cells can avoid the apoptotic effects of TRAIL by expressing decoy receptor. 3, 4 Although TRAIL seems to be an ideal cytokine for creating a selective and powerful antitumor effect, 5 there are two limitations to its clinical use, the instability of TRAIL protein and the resistance of some cancer cells to TRAIL.
Most preclinical trials with TRAIL have used sTRAIL proteins. Its stabilization as a trimer and its binding to DR4 and DR5 are key factors for effective TRAIL activity, as this improves its stability and biological activity. A trimer of TRAIL with leucine zipper (LZ) 6 has been widely used. Furthermore, in in vivo experiments, large amounts of TRAIL have been required to obtain tumor growth suppression, and a pharmacokinetic of TRAIL showed that most of the TRAIL had been eliminated 5 hours after intravenous injection. 6 The resistance of some cancer cells to TRAIL is another obstacle. The expression of decoy receptor, mutation of death receptor, 7 loss of caspase 8 and the production of inhibitors, such as cFLIP, [9] [10] [11] have all been identified as mechanisms. Many investigators have reported overcoming TRAIL resistance. Some chemotherapeutic agents have been shown to have potential to overcome TRAIL resistance by increasing death receptor expression. Cisplatin and etoposide 12 and paclitaxel restored TRAIL sensitivity in TRAIL-resistant cell lines by increasing DR5 expression. A subclinical dose of cisplatin and doxorubicin sensitized the most resistant colon cancer cell lines to TRAIL, not by inducing death receptor expression, but by lowering the threshold for TRAIL-induced procaspase 8 activation.
14 Adenoviral gene transfer of TRAIL to cancer tissues appears as an attractive alternative to sTRAIL, and resulted in the production of a stable TRAIL, and showed high local concentrations in cancer tissue, and possible bystander effects. Adenoviral gene transfers of TRAIL to cancer cells have already been reported. The transfer of the full-length cDNA of TRAIL induced the rapid production and expression of TRAIL, and subsequent tumor cell death mediated by an apoptotic mechanism. 15 In another experiment, Kagawa et al 16 also demonstrated the induction of apoptosis by adenovirus expressing TRAIL (ad-TRAIL), and they also showed the presence of a bystander effect mediated by surface expressed TRAIL contact, not by transfer in media.
In this study, we also constructed a replicationdefective adenovirus expressing the full-length cDNA of TRAIL with green fluorescent protein (GFP) (ad-TRAIL) and investigated its role in cancer treatment, especially in terms of overcoming TRAIL resistance and the induction of media-transferable bystander effects.
Materials and methods

Cell lines
Four human lung cancer cell lines (NCI H460, A549, NCI H157, NCI H358) and one normal bronchial epithelial cell line (BEAS2B) were purchased from the American Type Culture Collection (Manassas, VA). Three bladder cancer cell lines, one colon cancer cell line (HT29) and an ovarian cancer cell line (SKOV3) were obtained from the Korean Cell Line Bank (Seoul, Korea). A prostate cancer cell line (LNCaP) was obtained from Robert Matusik (Vanderbilt University Medical Center, Nashville, TN).
Construction of ad-TRAIL
Recombinant ad-TRAIL was generated using the AdEasy system (kindly provided by He T-C, Howard Hughes Medical Institute, Baltimore, MD). The fulllength cDNA of TRAIL was subcloned into the NotI site of pTRACK-CMV, which contained a green fluorescent protein (GFP) gene. The resulting pTRACK-CMV-TRAIL and pAdEasy1 were cotransformed into Escherichia coli BJ5183. pAd-TRAIL was generated by homologous recombination within E. coli. After selection with kanamycin, pAd-TRAIL was transfected into 293 cells, and the generation and propagation of ad-TRAIL were done in 293 cells. Ad-TRAIL was a defective virus with E1 and E3 deletion, which contained the GFP gene as an indicator of adenoviral infection. 17 Adenoviral stock was generated by CsCl ultracentrifugation and its titer was determined by standard plaque assay. Adenovirus-GFPlacZ (ad-lacZ) was used as a control virus. The presence of replication competent adenovirus was screened by PCR using primers specific for E1.
Transduction and transduction efficiency in human cancer cell lines
Cancer cell lines were cultured in complete media for at least 12 hours. Cells were then washed with phosphatebuffered saline (PBS), and adenoviral vector stocks in RPMI solution, at the indicated multiplicity of infection (moi), were added and the cells were incubated at 371C for 1 hour with gentle frequent agitation. Uninfected viruses were removed by PBS washing and cells were maintained in RPMI 1640 supplemented with 10% FBS. The transduction efficiency of cancer cell lines was measured by flow cytometry on a FACScan (Becton Dickson, San Jose, CA) without any additional staining.
Production of TRAIL from ad-TRAIL-infected cells
Human lung cancer cell lines (NCI H460 and A549) were transduced with ad-TRAIL (20 moi). TRAIL production was confirmed by Western blot assay with monoclonal antibody to TRAIL (Calbiochem, San Diego, CA) from the cell lysate taken 48 hours after transduction with ad-TRAIL. 18 Soluble TRAIL containing the active portion of TRAIL (amino acids 95-281) (Biomol, Plymouth, PA) was used as a positive control.
The same Western blot assay was repeated upon concentrated conditioned media. Lung cancer cells (NCI H460) were transduced with ad-TRAIL (20 moi) for 1 hour and uninfected adenoviruses were removed by washing with PBS. After 72 hours in serum-free RPMI 1640, when the cells showed apoptotic cell death, conditioned media and cell debris were separated by centrifugation. The conditioned media were concentrated using a Microcon YM-10 (Millipore, Bedford, MA), and Western blot was done.
Growth inhibitory effects of ad-TRAIL on cancer cell lines
After confirming TRAIL production from ad-TRAILinfected cells, the effects of ad-TRAIL on cancer cell growth were measured in three lung cancer cell lines (A549, NCI H358, NCI H460) and three bladder cancer cell lines (253J, T24, NCI H5637). Cells were incubated in 96-well plates and transduced with ad-TRAIL at the indicated moi for 1 hour and then further incubated for 48 hours. Viable cells were measured by standard MTT assay.
Comparison of ad-TRAIL and sTRAIL in cancer cell lines and a normal transformed cell line
To confirm the differential antitumor effect of ad-TRAIL and sTRAIL, we compared their antitumor effects on three resistant cancer cell lines (A549, SKOV3, HT29), one with intermediate sensitivity (NCI H157), one cell line sensitive to soluble TRAIL (NCI H460) and one normal bronchial epithelial cell line (BEAS2B). All cell lines were transduced with ad-TRAIL at the indicated moi or treated with sTRAIL (200-400 ng/ml). After 48 hours, the antitumor effects of ad-TRAIL and sTRAIL were compared by MTT assay.
Differential growth suppression because of ad-TRAIL or sTRAIL was confirmed by cell counting over 1 week. NCI H460, A549, SKOV3 and LNCaP were transduced with ad-TRAIL (20 moi) or treated with sTRAIL (300 ng/ ml). Cell numbers were counted daily with a hemocytometer and compared with those of ad-lacZ-transduced cells (relative cell viability).
Detection of ad-TRAIL-induced apoptosis by sub-G1 proportion assay
Sub-G1 proportion assays were performed to confirm apoptosis by ad-TRAIL or sTRAIL. Briefly, NCI H460 or A549 cells were transduced with ad-TRAIL (20 moi) or treated with sTRAIL (300 ng/ml). After 48 hours, cells were stained according to the manufacture's protocol (CycleTest plus kit, Becton Dickinson, San Jose, CA), and cells showing apoptosis were determined by counting the sub-G1 portion by flow cytometry.
Caspase-3 activation and inhibition assay
We investigated whether sTRAIL or ad-TRAIL induced apoptosis through caspase-3 activation in NCI H460 (sTRAIL-sensitive cell line) and A549 (sTRAIL-resistant cell line) using a colorimetric CaspACEt assay system (Promega). Inhibition of caspase-3 activation by tripeptide caspase inhibitor (z-VAD-FMK) was also investigated.
Cleavage of PARP by ad-TRAIL or sTRAIL in NCI H460 and A549
To confirm the differential effects of ad-TRAIL on NCI H460 and A549, cleavage of PARP was measured. Briefly, both cells were transduced with ad-TRAIL (30 moi) or treated with sTRAIL (300 ng/ml). Western blotting for PARP was performed to detect PARP cleavage in protein extracted at 4, 16 and 24 hours.
Bystander effect by conditioned-media transfer confirmed by Annexin V assay NCI H460 and A549 were transduced with ad-TRAIL (30 moi) for 1 hour. After washing off uninfecting virus, cells were maintained in complete media for 48 hours. The conditioned media were concentrated using a Centriplus-10 (Millipore, Bedford, MA) by 10-fold. The conditioned medium was then transferred to uninfected NCI H460 and A549 cells. Induction of apoptosis was measured by using the annexin V assay for apoptosis (PharMingen, San Diego, CA) at 24 hour.
Results
Transduction efficiency of ad-TRAIL by FACScan
Flow cytometry, without any staining, was used to determine the transduction efficiency of ad-TRAIL at 20 moi in cancer cell lines. The transduction efficiencies in the lung cancer cell lines (A549, NCI 460, NCI H157) were 55-70% (NCI H460: 59.14%) (Fig 1) . The transduction efficiencies in SKOV3 and BEAS2B were similar to those of the lung cancer cell lines; however, that of HT29 was low (8.23%).
Production of TRAIL protein from ad-TRAIL-transduced cells and confirmation of TRAIL protein in conditioned media
Western blot for TRAIL showed a 33 kDa-sized band in cell lysates. However, sTRAIL, used as a positive control, showed single band of 23 kDa (Fig 2a) . In this assay, we did not find a dimer or trimer band of TRAIL, as detected in a previous report, 15 probably because of the denaturing nature of the gel. TRAIL (33 kDa) was also found in the conditioned media of ad-TRAIL-transduced cells (Fig  2b) . The size difference between this TRAIL and sTRAIL suggest that this TRAIL protein was not actively secreted after the processing from ad-TRAIL-transduced cells but was passively released from apoptotic cells.
Strong cytotoxic effects of ad-TRAIL in various cancer cell lines
In three lung cancer and three bladder cancer cell lines tested, transduction with ad-TRAIL showed a strong cytotoxic effect by MTT assay (Fig 3) . Interestingly ad-TRAIL also showed a strong cytotoxic effect in A549, which is a known TRAIL-resistant cell line.
5,19
Ad-TRAIL induced cytotoxicity in several cancer cell lines resistant to sTRAIL.
Transduction with ad-TRAIL (10-50 moi) exhibited strong cytotoxic effects on A549 and SKOV3, which are resistant to sTRAIL (200-400 ng/ml). Ad-TRAIL also showed moderate cytotoxic effects on HT-29 that was resistant to sTRAIL and also resistant to adenovirus transduction because of its paucity of Coxsackie adenoviral receptor (CAR). However, both ad-TRAIL and sTRAIL (300 ng/ml) showed very strong cytotoxic effect in NCI H460 (sTRAIL-sensitive cell line). A normal bronchial epithelial cell line (BEAS2B) showed only weak sensitivity to ad-TRAIL compared to other cancer cell lines (Fig 4) . These differences in cytotoxicity were confirmed again by serial cell counting. Both ad-TRAIL and sTRAIL induced strong growth suppression in NCI 460. However, only ad-TRAIL induced growth suppression in A549, SKOV3 and LNCaP (Fig 5) .
Induction of apoptosis by ad-TRAIL by sub-G1 proportion assay
Sub-G1 proportion assays showed the induction of apoptosis by ad-TRAIL in all cancer cell lines tested (sub-G1 fraction: 27.14% in NCI H460, 32.76% in A549, 13.13% in SKOV3; data not shown). However, sTRAIL (300 ng/ml) failed to induce apoptosis in the sTRAILresistant cell lines (sub-G1 fraction: 1.33% in A549, 0.68% in SKOV3; data not shown), but induced apoptosis in sTRAIL-sensitive cell line (sub-G1 fraction: 22.08% in NCI H460) (Fig 6) .
Differential effects of sTRAIL and ad-TRAIL on caspase-3 activation and inhibition assay
A CaspACE TM assay also showed the differential effects of sTRAIL and ad-TRAIL. In NCI H460 (sTRAIL sensitive cell line), both sTRAIL (300 ng/ml) and ad-TRAIL (30 moi) induced caspase-3 activation, manifested by the lysis of caspase-3 substrate (Ac-DEVD-pNA), and z-VAD-FMK (tripeptide caspase inhibitor) inhibited both sTRAIL-and ad-TRAIL-induced lysis. In A549 cells, only ad-TRAIL induced the activation of caspase-3 that was blocked by z-VAD-FMK; however, sTRAIL failed to activate caspase-3 (Fig 7) .
Differential cleavage of PARP by ad-TRAIL and sTRAIL in NCI H460 and A549 cells
The apoptotic effect on of sTRAIL and ad-TRAIL in sTRAIL-resistant cell line was confirmed by PARP (substrate of caspase 3) cleavage assay. Both ad-TRAIL and sTRAIL induced the cleavage of PARP in NCI H460, however, only ad-TRAIL induced the cleavage of PARP in A549 (Fig 8) .
Presence of a media-transferable bystander effect only in NCI H460 cells
The concentrated conditioned media from ad-TRAILtransduced NCI-H460 induced apoptosis in untransduced NCI H460 (early apoptotic proportion: 15.42%). However, that from ad-TRAIL-transduced A549 failed to induce apoptosis in untransduced A549 versus the control (early apoptotic proportion: 2.42%) (Fig 9) .
Discussion
The instability and high cost of sTRAIL is a major limitation of current TRAIL usage. 6 Furthermore, the TRAIL resistance of some cancer cells is another limitation of TRAIL in cancer treatment. In this study, we developed a recombinant adenovirus expressing the whole cDNA of human TRAIL (ad-TRAIL), and demonstrated that this virus can overcome these two limitations.
After the generation of ad-TRAIL by the ad-Easy system, Western blot assay showed that ad-TRAILinfected cells contained a large amount of 33 kDa TRAIL protein, cf. sTRAIL protein at 23 kDa, attributed to the ad-TRAIL containing the full-length cDNA of TRAIL. Furthermore, we found the TRAIL of 33 kDa in the concentrated media of ad-TRAIL-infected cancer cells. The difference in the sizes of these TRAILs suggests that the 33 kDa TRAIL protein was not actively secreted from ad-TRAIL-transduced cells but passively released from apoptotic cells. This is a very important finding and the basis of the bystander effect.
The antitumor effects of ad-TRAIL were tested on three lung and three bladder cancer cells lines. Ad-TRAIL showed very potent cytotoxic effects in all cell lines tested (Fig 3) . Among them, A549 was previously known to be resistant to sTRAIL, 5, 19 however, ad-TRAIL showed almost the same cytotoxic effect as in the other cell line (NCI H460). We selected several cancer cell lines known to be resistant to TRAIL (SKOV3, HT29 and LNCaP). A549 and SKOV3 showed high sensitivity to ad-TRAIL but little susceptibility to sTRAIL. Sub-G1 proportion assay showed that cell death in A549 and SKOV3 was because of apoptosis. HT29, resistant to adenoviral infection because of paucity of CAR, showed moderate sensitivity to ad-TRAIL. LNCaP, another resistant cell line to TRAIL by PTEN mutation, 20 also showed sensitivity to ad-TRAIL.
Normal transformed bronchial cell line (BEAS2B), even though sensitive to adenoviral infection, was very weakly sensitive to ad-TRAIL. In addition to BEAS2B, Lin et al 21 reported that adenovirus-GFP/TRAIL elicited antitumor effects, without toxic effects, on primary hepatocytes.
Generally, ad-TRAIL showed moderate to high sensitivity in sTRAIL-resistant cell lines. In a previous report, 15 ad-TRAIL failed to induce apoptosis in WM 164 (melanoma), which was resistant to sTRAIL because of high intracellular cFLIP. We did not test our adenovirus in this cell line. In another report on ad-TRAIL, it was shown that ad-TRAIL induced apoptosis in A549, but it was not mentioned that 
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OD (540nm) OD(540nm) Figure 4 Ad-TRAIL induced cytotoxicity in several cancer cell lines resistant to sTRAIL. Ad-TRAIL (10-50 moi) exhibited strong cytotoxic effects on A549 and SKOV3, which are resistant to sTRAIL (200-400 ng/ml) and moderate cytotoxic effects on HT29, also resistant to sTRAIL and to adenovirus transduction because of paucity of CAR. Both ad-TRAIL and sTRAIL (300 ng/ml) strongly induced apoptosis in NCI H460 (sTRAILsensitive cell line). Ad-TRAIL showed very weak growth suppression in a normal bronchial epithelial cell line (BEAS2B). (32.76%) (1.33%) (%: sub-G1 fraction) (22.08%) (27.14%) Figure 6 Differential induction of apoptosis by ad-TRAIL and sTRAIL in NCI H460 and A549. Sub-G1 assay revealed that ad-TRAIL (20 moi) induced apoptotic cell death in NCI H460 (27.14%; sub-G1 fraction) and A549 (32.76%), however, sTRAIL (300 ng/ml) induced apoptotic cell death in NCI H460 only (22.08%), and not in A549 (1.33%).
A549 is resistant to sTRAIL. 16 However, two recent reports have suggested that the ad-TRAIL overcomes TRAIL resistance. Voelkel-Johnson et al, 22 demonstrated that ad-TRAIL-induced apoptotic cell death in TRAIL-resistant prostate cancer cell lines that was inhibited by caspase inhibition. Lin et al 23 also demonstrated that treatment with ad-GFP-TRAIL with hTERT promoter induced apoptotic cell death in breast cancer cell lines resistant to sTRAIL (MCF7 and MDA-MB-453).
Two lung cancer cell lines (NCI H460: sensitive to sTRAIL, A549: resistant to sTRAIL) were selected to confirm this differential effect of ad-TRAIL and sTRAIL, and to compare the activation of the apoptotic pathway. Both cell lines were similarly sensitive to adenoviral transduction. In NCI H460 cells, both ad-TRAIL and sTRAIL activated the apoptotic pathway, as confirmed by a caspase-3 activation/inhibition assay and PARP cleavage. However, only ad-TRAIL activated the apoptotic pathway in A549. The mechanistic explanation for this difference has not yet been elucidated. Recently, Zhang et al 24 selected the resistant clone of DLD1 colon cancer cell line to adenovirus-TRAIL(DLD1/TRAIL-R) even though parental DLD1 was sensitive to ad-TRAIL. They found this selected resistance was related to the TRAIL gene and that DLD1/ TRAIL was sensitive to adenovirus expressing the Bax or the Bak gene.
Another important finding of the present study is the presence of a bystander effect of ad-TRAIL, which has been demonstrated previously. 16 However, the bystander effect of ad-TRAIL was not transferable Figure 7 Caspase-3 activation and inhibition assay confirmed the differential effects of sTRAIL and ad-TRAIL. CaspACE TM assay (Caloric, Promega) also showed the differential effect of sTRAIL and ad-TRAIL. Ad-TRAIL induced the activation of caspase-3, which was inhibited by z-VAD-FMK in NCI H460 and A549. However, sTRAIL failed to induce caspase-3 activation in A549. with medium. In mixed culture, they showed that the bystander effect could be elicited by direct contact between surfaces expressing TRAIL and the death receptors of neighboring cells. In contrast, we found that the bystander effect was transferred in the conditioned medium, and this was confirmed by the induction of apoptosis. Annexin V assay showed that apoptosis was induced by conditioned media transfer in NCI H460 but not in A549. The bystander effect seemed to be present only in the sTRAIL-sensitive cell line. As mentioned previously, Western blot assay of concentrated media showed the presence of full-length TRAIL protein of 33 kDa (Fig 2) . Differences between full-length TRAIL protein in media and the soluble form of TRAIL suggest that full-length TRAIL is passively released from dying cells because of apoptosis. Therefore, we expect that this bystander effect is shown in only sTRAIL-sensitive cell lines because of the necessity of binding of TRAIL to death receptors on the cell surface. Actually, in our experiment, the bystander effect was not evident in A549, an sTRAIL-resistant cell line even though this cell line was sensitive to ad-TRAIL-induced apoptosis.
In the clinical situation, a media-transferable bystander effect is much more valuable than a contact-mediated bystander effect. The major limitation of locally acting gene therapies, such as tumor suppressor gene therapies and proapoptotic gene therapies like TRAIL, is the low-transduction efficiency in tumors. The bystander effect is a very important characteristic, which has the potential to overcome this limitation. Theoretically, a medium transferable bystander effect has a broader influence than a direct contact-mediated bystander effect. Furthermore, the absence of the bystander effect in TRAIL-resistant cells may be valuable because it avoids toxic effects to neighboring normal cells.
From these observations, we presume that the intracellular pathway of ad-TRAIL-induced apoptosis differs from its media transferable-bystander effect.
In conclusion, two novel characteristics of adenovirus expressing full-length TRAIL were found. First, ad-TRAIL can induce apoptotic cell death even in several cancer cell lines resistant to sTRAIL. Second, ad-TRAIL induced a bystander effect that was transferable by media, and which has the potential to increase its therapeutic value by overcoming the locally acting nature and the low-transduction rate of the alternatives in clinical situations.
Future study will focus on the testing of ad-TRAIL in a wide range of TRAIL-resistant cell lines and on the intracellular mechanism of ad-TRAIL. Abbreviations TRAIL, Tumor necrosis factor related apoptosis inducing ligand; Ad-TRAIL, Adenovirus expressing TRAIL; sTRAIL, soluble TRAIL; CAR, Coxsackie adenoviral receptor.
